1. Physician Survey Executive Summary. Ironwood Pharmaceuticals. 2016.
2. Perez-Ruiz F, Herrero-Beites A. Evaluation and Treatment of Gout as a Chronic Disease. Adv Ther. 2012;29(11):935–946.
3. Schumacher HR. The pathogenesis of gout. Cleve Clin J Med. 2008;75(5):S2-S4.
4. Zhu Y, et al. Prevalence of Gout and Hyperuricemia in the US General Population. Arthritis Rheum. 2011;63:3136–41.
5. Richette P, Bardin T. Gout. Lancet. 2010;375(9711):318-328.
6. Khanna D, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64:1431-1446.
7. Scott J, Pollard A. Uric acid excretion in the relatives of patients with gout. Ann. Rheum. Dis. 1970;29(4):397-400.
8. Juraschek SP, et al. Gout, Urate Lowering Therapy and Uric Acid Levels among US Adults. Arthritis Care Res. 2015;67(4):558-592.
9. Wood R, et al. Patients with Gout Treated with Conventional Urate-lowering Therapy: Association with Disease Control, Health-related Quality of Life, and Work Productivity. J Rheumatol. 2016;1-7.
10. Khanna P, et al. A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift. Postgrad Med. 2016;128(1):34-40.
11. Meyer M, et al. Trends in Medication Utilization and the Cost of Treatment for Gout. Am J Pharmacy Ben. 2015;5(3):123-128.
12. Primatesta P, et al. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskeletal Dis. 2011;12:130:1-7.
13. Singh JA, Akhras KS and Shiozawa A. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Res & Ther. 2015;17:120:1-12.
14. AZN/Decision Resource Market Research.